Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day

June 9, 2026

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

June 2, 2026

Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003

May 19, 2026

Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026

May 15, 2026

Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders

May 13, 2026

Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model

May 5, 2026

Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum

April 21, 2026

Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

April 17, 2026

Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

April 16, 2026

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

March 31, 2026

1
2
3
…
19
›